Medytox (KRX 086900) Stock Outlook 2026 covering the Meditoxin, Coretox and Newlux botulinum toxin lineup, hyaluronic acid fillers, China approval and US expansion, the Daewoong strain lawsuit and regulatory risk, a Korean toxin peer comparison, and what global investors should watch.
A qualitative 2026 stock outlook for Pharma Research (KRX 214450), the Korean aesthetics-bio company behind Rejuran, a salmon-DNA PN/PDRN skin booster. We cover its brand moat, expansion into fillers, toxin, and cosmetics, high margins, the growth-premium valuation risk, competition from Hugel and others, overseas approval hurdles, and how global investors should frame the KRW-listed shares.
A deep, qualitative 2026 outlook on Daewoong Pharmaceutical (KRX 069620): the Nabota botulinum toxin (sold as Jeuveau in the US), the winding down of the Medytox litigation, the P-CAB reflux drug Fexuclue, the SGLT-2 diabetes drug Envlo, overseas license-out royalties, the pipeline, and the R&D cost burden for global investors.
Hugel (KRX 145020) 2026 stock outlook. A deep qualitative analysis of its botulinum toxin (Botulax/Letybo) and HA filler (The Chaeum) business, the US FDA approval and American aesthetics market entry, China and Europe expansion, the GS Group consortium acquisition, the toxin strain-origin litigation risk, and how a Korean challenger competes against the global Big 3.